Established in 1982 and headquartered in Slough, near London, England, Chiltern is a leading global contract research organisation. The Company has extensive experience running and staffing international Phase I to Phase IV clinical trials accross a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1200 people with offices in the United States, United Kingdom, Germany, France, Italy, Spain, Russia, Poland, Czech Republic, Ukraine, India, and South Africa. Chiltern provides services including Phase I and laboratory support, Phase II — III Clinical Development, Staff Resourcing, Biometrics, Regulatory and Medical Affairs.

Czura Thornton (GP) Limited acquired Chiltern in July 2006 on behalf of the Galaxy Limited Partnership.

www.chiltern.com

Glenn Kerkhof — Chief Executive Officer.  BCom, MBA

Glenn joined Chiltern as Chief Executive Officer in August 2006. Prior to this he was General Manager Operations for the global clinical research business of Charles River Laboratories (CRL:NYSE), formely part of Inveresk Research Group. Glenn brings 13 years industry experience to Chiltern and with his management team and support  from Czura Thornton has established Chiltern as a fast growing, high quality supplier of clinical research services and contract personnel to pharmaceutical and biotechnology clients worldwide.

Roland Boyd — Chief Financial Officer. BA, FCA

Roland was formerly Group Financial Controller of Inveresk Research Group, Inc. (IRGI:NASD) and prior to that spent 20 years with Arthur Anderson latterly as an audit partner. Mr Boyd has extensive experience in financial roles including auditing, taxation and mergers and acquistions.